Corcept Therapeutics (CORT) Price & Analysis

Compare

1,047 Followers

CORT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$32.33 - $117.33

Previous CloseN/A

Volume78.39K

Average Volume (3M)1.26M

Market Cap

$7.12B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)58.3

Beta0.25

Next Earnings

Oct 29, 2025

EPS Estimate

0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.29

Shares Outstanding106,044,690

10 Day Avg. Volume798,518

30 Day Avg. Volume1,264,780

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$134.50

Price Target Upside94.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Pipeline StrengthUpcoming events in 2H25 will continue to underscore the strength of the commercial and clinical pipeline.

Product Approval PotentialRelacorilant could potentially receive a positive decision with a broad label from the US regulatory agency based on strong safety and efficacy data.

Supply Chain ImprovementA second specialty pharmacy is expected to be fully operational soon, which could improve supply chain efficiency.

Bears Say

Intellectual Property UncertaintyThe appellate court decision on Korlym IP is expected to be a stock-moving event, which adds uncertainty to the stock.

Revenue Guidance DowngradeThe company revised 2025 revenue guidance downwards by $50M due to ongoing supply chain issues.

Sales Weakness1Q sales of Korlym are expected to be weak sequentially due to seasonal need for prior-authorization re-ups and a 4Q distribution hiccup.

Corcept Therapeutics News

Corcept Therapeutics price target lowered to $121 from $131 at Piper Sandler

Piper Sandler analyst David Amsellem lowered the firm’s price target on Corcept Therapeutics (CORT) to $121 from $131,...

1d ago

CORT

Corcept Therapeutics price target lowered to $137 from $142 at Canaccord

Canaccord analyst Edward Nash lowered the firm’s price target on Corcept Therapeutics (CORT) to $137 from $142 and...

1d ago

CORT

Corcept Therapeutics reports Q2 EPS 29c, consensus 19c

Reports Q2 revenue $194.4M, consensus $199.4M. “The second quarter marked another period of robust growth in our hypercortisolism...

2d ago

CORT

Piper Sandler pharmaceuticals analyst holds analyst/industry conference call

Pharmaceuticals analysts sizes up the data for Corcept Therapeutics (CORT)’ Relacorilant in ovarian cancer on an Analyst/Industry conference...

24d ago

CORT

Corcept Therapeutics’ Earnings Call: Growth Amid Challenges

Corcept Therapeutics (($CORT)) has held its Q2 earnings call. Read on for the main highlights of the call....

20h ago

CORT

Corcept Therapeutics: Buy Rating Backed by Strategic Growth Initiatives and Promising Product Launches

Analyst Swayampakula Ramakanth of H.C. Wainwright reiterated a Buy rating on Corcept Therapeutics, retaining the price target of...

1d ago

CORT

Corcept Therapeutics Reports Revenue Growth Amid Rising Expenses

Corcept Therapeutics ( ($CORT) ) has released its Q2 earnings. Here is a breakdown of the information Corcept...

2d ago

CORT

Corcept Therapeutics Reports Q2 2025 Financial Results

An update from Corcept Therapeutics ( ($CORT) ) is now available. On July 31, 2025, Corcept Therapeutics announced...

2d ago

CORT

Corcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome

Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical study. Corcept Therapeutics is conducting an extension study...

3d ago

CORT

Is CORT a Buy, Before Earnings?

Corcept Therapeutics (CORT) is scheduled to report 2nd quarter earnings on 07/31/2025, after the market closes. Regarding Q2...

4d ago

CORT

Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension

Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical study. Corcept Therapeutics is conducting a study titled...

5d ago

CORT

Corcept Therapeutics’ ALS Study: A Potential Game-Changer?

Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical study. Corcept Therapeutics is conducting a Phase 2...

8d ago

CORT

Corcept Therapeutics Submits New Drug Application to FDA

The latest update is out from Corcept Therapeutics ( ($CORT) ). On July 14, 2025, Corcept Therapeutics announced...

19d ago

CORT

Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension

Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical study. Corcept Therapeutics is conducting a study titled...

24d ago

CORT

CORT FAQ

What was Corcept Therapeutics Inc.’s price range in the past 12 months?

Corcept Therapeutics Inc. lowest stock price was $32.33 and its highest was $117.33 in the past 12 months.

What is Corcept Therapeutics Inc.’s market cap?

Corcept Therapeutics Inc.’s market cap is $7.12B.

When is Corcept Therapeutics Inc.’s upcoming earnings report date?

Corcept Therapeutics Inc.’s upcoming earnings report date is Oct 29, 2025 which is in 88 days.

How were Corcept Therapeutics Inc.’s earnings last quarter?

Corcept Therapeutics Inc. released its earnings results on Jul 31, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.188 by $0.102.

Is Corcept Therapeutics Inc. overvalued?

According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corcept Therapeutics Inc. pay dividends?

Corcept Therapeutics Inc. does not currently pay dividends.

What is Corcept Therapeutics Inc.’s EPS estimate?

Corcept Therapeutics Inc.’s EPS estimate is 0.17.

How many shares outstanding does Corcept Therapeutics Inc. have?

Corcept Therapeutics Inc. has 106,044,690 shares outstanding.

What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?

Corcept Therapeutics Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.188. Following the earnings report the stock price went up 2.724%.

Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?

Currently, no hedge funds are holding shares in CORT

Corcept Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

21.42%

Trailing 12-Months

Asset Growth

12.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corcept Therapeutics Inc.

Corcept Therapeutics (CORT) is a pharmaceutical company that specializes in the development and commercialization of drugs that modulate the effects of cortisol, a hormone produced by the adrenal gland. The company is primarily focused on addressing unmet medical needs in metabolic, oncologic, and psychiatric disorders through its proprietary selective cortisol receptor modulators. Corcept's flagship product, Korlym, is approved for the treatment of Cushing's syndrome in the United States.

Corcept Therapeutics (CORT) Earnings & Revenues

CORT Earnings Data >

CORT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted impressive revenue growth and significant advancements in clinical trials, suggesting a strong commercial outlook. However, these were tempered by supply chain challenges and ongoing patent litigation, leading to a mixed outlook.Read More>

CORT Stock 12 Month Forecast

Average Price Target

$134.50

▲(94.93%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","62":"$62","90":"$90","118":"$118","146":"$146"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$134.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$121.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,62,90,118,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69,74.84615384615384,80.6923076923077,86.53846153846153,92.38461538461539,98.23076923076923,104.07692307692307,109.92307692307692,115.76923076923077,121.61538461538461,127.46153846153845,133.30769230769232,139.15384615384613,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69,74.03846153846153,79.07692307692308,84.11538461538461,89.15384615384616,94.1923076923077,99.23076923076923,104.26923076923077,109.3076923076923,114.34615384615384,119.38461538461539,124.42307692307692,129.46153846153845,{"y":134.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69,73,77,81,85,89,93,97,101,105,109,113,117,{"y":121,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.93,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >